Default company panoramic image

Endothelix, Inc.

Endothelix is a cardiovascular device company. Our first product, VENDYS®, is FDA cleared, reimbursable and is generating revenue today.

  • Stage $1M in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Houston, TX, USA
  • Currency USD
  • Founded October 2003
  • Employees 11
  • Website

Company Summary

Endothelix is a cardiovascular diagnostic company with an FDA cleared device (VENDYS®), a pipeline, and a pioneering team. Technology licensed from the Texas Heart Institute detects Endothelial Dysfunction, an early biomarker of CVD and an indicator of response to drug therapies. A simple, non-invasive, reimbursable (~$175) test done in a doctor’s office We are seeking series B investors to expand our sales team and conduct a new clinical trial.


  • Default avatar
    Haider Hassan
    VP, Product Development

    Distinguished Systems Engineer with degrees in both Mathematical Sciences and Computer Systems Engineering. Extensive experience in project management and product development in the fields of biomedical devices, software engineering, embedded systems, robotics, real-time DSP, and automation. Responsible for all Endothelix projects including the VENDYS® product line. Actively participates in research, SW/HW development and regulatory affairs..

  • Default avatar
    Morteza Naghavi
    President and CEO

    Dr. Naghavi is an innovative physician scientist and entrepreneur with special interests in the fields of cardiovascular medicine and medical technologies. As a former cardiology faculty at the UT Health Science Center and Director of the Vulnerable Plaque Research Department at the Texas Heart Institute, he contributed to several inventions and to creating the field of “vulnerable plaque”. Dr. Naghavi is the founder of Endothelix.

  • Default avatar
    Albert Yen
    VP, Medical Affairs

    M.D., Baylor College of Medicine. Specialized in Clinical Neurology during residency and fellowship at BCM and Methodist. Over 12 years of experience in basic and clinical research in the areas of neurovascular and neuroinflammatory disorders. Power 3 Medical and In3 Ventures were some of his early business experiences. He joined Endothelix in 2007 as VP of Medical Affairs and helped advance the company through clinical trials.

  • Default avatar
    Will Sotka
    VP of Sales and Marketing

    Will has over 13 years of sales experience in a diverse background of medical technology, with an emphasis on vascular diagnostics. He developed strategic sales plans that replicated high levels of clinical and research adoption of new medical technologies while establishing the initial reimbursement history and increasing research publications by luminary/KOL's in clinical and academic institutions.

Previous Investors

  • Default avatar
    Texas Emerging Technolgy Fund
    Default avatar
    Houston Angel Network Members
    Default avatar
    Founders and various Angel Investors